|
|
 |
|
Viewing report
|
|
|
|
Report on Antihypertensive Drug Market
Sunfaith China Ltd, May 2009, Pages: 15
It is learned that China's hypertension morbidity rate of adults is 18.8%, treatment rate is 6.1%, and it also takes on a lowering trend of age, which attracting more and more people's attention on hypertension. Thus there is a greater demand for antihypertensive drug, and China's market scale of antihypertensive drug is still very huge in the future.
This report carries out specific analysis and research of three major antihypertensive drug types, i.e. classification of current hypertension, and drug market competition. It points out that although there is a huge market demand of antihypertensive drug, the competition is still fierce.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Antihypertensives Market to 2016 - Generic Erosion Following Patent Expiry of Major ARBs to Impact the Market
Hypertension: Treatments and Prescribing Practices - A Global Survey
Hypertension: Competing Treatments and Market Entry Considerations
Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion
Handbook of Hypertension
Anti-Hypertensive Drugs - Global Strategic Business Report
The Global Market for Fixed-Dose Combination Drugs for Leading Diseases
Cardiovascular Drug Delivery - Technologies, Markets and Companies
Problem Solving in Hypertension
Endpoints - Clinical Trials in Cardiovascular Disorders - Optimal Use of Surrogate Endpoints and Clinical Biomarkers are Key Determinants of Success
|
|
|
|
